KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of “Buy” from Analysts

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have received an average recommendation of “Buy” from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $26.4286.

KALV has been the subject of several recent research reports. Leerink Partners boosted their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, July 7th. HC Wainwright boosted their price target on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday. Finally, JMP Securities boosted their price target on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a research note on Friday.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,336 shares of the company’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $13.42, for a total transaction of $31,349.12. Following the completion of the sale, the insider directly owned 122,505 shares in the company, valued at $1,644,017.10. This represents a 1.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Benjamin L. Palleiko sold 7,294 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $15.84, for a total value of $115,536.96. Following the sale, the chief executive officer owned 395,189 shares of the company’s stock, valued at $6,259,793.76. The trade was a 1.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 59,835 shares of company stock valued at $892,350 over the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in KALV. Suvretta Capital Management LLC lifted its stake in shares of KalVista Pharmaceuticals by 16.6% in the 4th quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company’s stock valued at $41,613,000 after acquiring an additional 701,007 shares during the last quarter. Tang Capital Management LLC lifted its stake in shares of KalVista Pharmaceuticals by 13.2% in the 4th quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company’s stock valued at $41,451,000 after acquiring an additional 572,300 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its stake in shares of KalVista Pharmaceuticals by 32.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock valued at $41,400,000 after acquiring an additional 1,200,000 shares during the last quarter. Vestal Point Capital LP lifted its stake in shares of KalVista Pharmaceuticals by 19.3% in the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company’s stock valued at $40,402,000 after acquiring an additional 770,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of KalVista Pharmaceuticals by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company’s stock valued at $26,526,000 after acquiring an additional 43,355 shares during the last quarter.

KalVista Pharmaceuticals Trading Down 5.4%

Shares of KALV stock opened at $14.01 on Friday. The stock has a market cap of $705.26 million, a P/E ratio of -3.56 and a beta of -0.10. The stock has a 50 day simple moving average of $14.14 and a 200 day simple moving average of $12.79. KalVista Pharmaceuticals has a 1 year low of $7.30 and a 1 year high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.21). The company had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.97 million. Analysts forecast that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).